Table 1.
Studies and patient characteristics in this review.
| Study | Year | Study design | No of patients | No of embolizations | Age (mean) | Male (%) | Unilateral/Bilateral | Symptomatic cSDH (%) | Antithrombotic therapy (%) |
|---|---|---|---|---|---|---|---|---|---|
| Kim et al. (5) | 2017 | Retrospective | 20 | 20* | 73.7 | 14 (70.0) | 14/6 | 20 (100) | 9 (45.0) |
| Ban et al. (9) | 2018 | Retrospective | 72 | 72* | 69.5 | 48 (66.7) | 53/19 | 45 (62.5) | 29 (40.3) |
| Waqas et al. (10) | 2019 | Retrospective | 8 | 8 | 63.6 | 5 (62.5) | 7/1 | 8 (100) | 8 (100) |
| Saitoh et al. (11) | 2019 | Retrospective | 8 | 8* | 79 | 8 (100) | 6/2 | NR | 2 (25.0) |
| Okuma et al. (4) | 2019 | Retrospective | 17 | 17* | 76.4 | 12 (70.6) | 13/4 | 17 (100) | 11 (64.7) |
| Nakagawa et al. (12) | 2019 | Retrospective | 20 | 20* | 78.3 | 14 (70) | 12/8 | 20 (100) | 4 (20.0) |
| Link et al. (13) | 2019 | Retrospective | 49 | 60 | 69 | 32 (65.3) | 38/11 | NR | 39 (77.5) |
| Yajima et al. (14) | 2020 | Retrospective | 18 | 18* | 78.5 | 16 (88.9) | 15/3 | NR | 3 (16.7) |
| Shotar et al. (15) | 2020 | Retrospective | 89 | 89* | 74 | 68 (76.4) | 74/15 | 89 (100) | 71 (79.7) |
| Rajah et al. (16) | 2020 | Prospective | 46 | 46* | 71.7 | 31 (67.3) | 40/6 | 44 (100) | 14 (31.8) |
| Ng et al. (17) | 2020 | Prospective randomized | 19 | 22 | 77.4 | 10 (52.9) | 16/3 | 19 (100) | 7 (31.8) |
| Mureb et al. (18) | 2020 | Retrospective | 8 | 8 | 75.4 | 7 (87.5) | 8/0 | NR | NR |
| Joyce et al. (19) | 2020 | Retrospective | 121 | 151 | 77.5 | 99 (81.8) | 91/30 | NR | 66 (54.3) |
| Fan et al. (20) | 2020 | Retrospective | 7 | 7 | NR | NR | 7/0 | 7 (100) | NR |
| Wei et al. (21) | 2021 | Retrospective | 10 | 20 | 63.3 | 10 (100) | 0/10 | 10 (100) | NR |
| Tiwari et al. (22) | 2021 | Retrospective | 10 | 13 | 71.4 | NR | 7/3 | 10 (100) | 6 (60.0) |
| Tanoue et al. (23) | 2021 | Retrospective | 15 | 15 | 78 | 10 (66.7) | 15/0 | 15 (100) | 1 (6.6) |
| Schwarz et al. (24) | 2021 | Retrospective | 41 | 44 | 73.3 | 33 (75.0) | 38/3 | 44 (100) | 19 (43.1) |
| Petrov et al. (25) | 2021 | Retrospective | 10 | 15 | 66 | 7 (70.0) | 5/5 | 10 (100) | 0 (0) |
| Lee et al. (26) | 2021 | Retrospective | 22 | 31 | 63.9 | 16 (72.7) | 13/9 | 31 (100) | 4 (18.2) |
| Kan et al. (27) | 2021 | Prospective | 138 | 138* | 69.8 | 98 (71.0) | 122/16 | NR | 72 (52.2) |
| Gomez-Paz et al. (28) | 2021 | Retrospective | 23 | 27 | 74 | 10 (43.5) | 19/4 | 20 (87.0) | 13 (56.5) |
| scovile et al. (29) | 2022 | Retrospective | 208 | 208 | NR | 115 (55.3) | NR | NR | 106 (52.0) |
| Saway et al. (30) | 2022 | Retrospective | 100 | 100* | 73 | 68 (68.0) | 64/32 | 97 (97) | 66 (66.0) |
| Samarage et al. (31) | 2022 | retrospective | 37 | 37* | 76.9 | 25 (67.6) | 23/15 | 26 (70) | 17 (45.9) |
| Salie et al. (32) | 2022 | Retrospective | 52 | 52 | 74.2 | 38 (73.1) | 52/0 | 47 (90.4) | 37 (71.2) |
| Onyinzo et al. (33) | 2022 | Retrospective | 50 | 50 | 79.6 | 42 (84.0) | 50/0 | NR | 35 (70.0) |
| Mir et al. (34) | 2022 | Retrospective | 56 | 56* | 73 | 43 (76.8) | 51/5 | NR | 23 (41.1) |
| Magidi et al. (35) | 2022 | Retrospective | 61 | 61* | 62.5 | 48 (78.7) | 39/22 | NR | 34 (55.8) |
| Khorasanizadeh et al. (36) | 2022 | Retrospective | 78 | 94 | 72 | 50 (64.1) | 62/32 | 65 (83.3) | 52 (66,7) |
| Housley et al. (37) | 2022 | Retrospective | 44 | 48 | 73.3 | 25 (56.8) | 40/4 | NR | 21 (47.7) |
| Fuentes et al. (38) | 2022 | Retrospective | 322 | 322 | NR | 228 (70.8) | NR | NR | 58 (18.0) |
| Enriquiz-Marulanda et al. (39) | 2022 | Retrospective | 36 | 45 | 76 | 28 (62.2) | 27/9 | 43 (95.6) | 34 (75.5) |
| Dofuku et al. (40) | 2022 | Retrospective | 9 | 9 | 85 | 6 (66.7) | 9/0 | 9 (100) | 5 (55.5) |
| Catapano et al. (41) | 2022 | Retrospective | 66 | 84 | 70 | 51 (77.3) | 48/18 | 50 (75.8) | 32 (48.5) |
| Carpenter et al. (42) | 2022 | Retrospective | 23 | 23* | 80 | 15 (65.2) | 13/10 | NR | 20 (87.0) |
| Wali et al. (43) | 2023 | Retrospective | 8 | 8 | 80.5 | 6 (75.0) | 3/5 | NR | NR |
| Shehabeidin et al. (44) | 2023 | Retrospective | 97 | 97 | 78 | 71 (73.2) | NR | NR | 50 (51.5) |
| Seok et al. (45) | 2023 | Retrospective | 9 | 13 | 77.3 | 8 (88.8) | 13/0 | 13 (100) | 7 (77.7) |
| Salem et al. (46) | 2023 | Retrospective | 530 | 636 | 71.9 | 38 6(72.8) | 424/106 | NR | 281 (53.0) |
| Martinez-Gutierrez et al. (47) | 2023 | Retrospective | 57 | 66 | 66 | 45 (78.9) | 48/9 | NR | 28 (49.5) |
| Liu et al. (48) | 2023 | Retrospective | 53 | 53 | 68.1 | 42 (79.2) | 53/0 | NR | 20 (38.7) |
| Krothapalli et al. (49) | 2023 | Retrospective | 116 | 116 | NR | 80 (68.9) | 116/0 | NR | 80 (69.0) |
| 2,783 | 3,027 | 71.2 | 1,968 (71.1) | 1,748/435 | 759 (90.6) | 1,384 (50.3) |
cSDH, chronic subdural hematoma; NR, not reported. *Treatment of bilateral cSDH counted as one treatment.